Published in J Cell Biochem on February 01, 2010
In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med (2015) 1.83
Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J (2011) 0.99
How B cells influence bone biology in health and disease. Bone (2010) 0.94
In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone (2013) 0.94
Hypercalcemia of Malignancy: An Update on Pathogenesis and Management. N Am J Med Sci (2015) 0.90
Mechanisms of multiple myeloma bone disease. Bonekey Rep (2012) 0.88
Myeloma bone disease: Pathophysiology and management. J Bone Oncol (2013) 0.87
Discovering the meaning of monoclonal gammopathy of undetermined significance: current knowledge, future challenges. Transl Med UniSa (2014) 0.82
Osteogenic inhibition in multiple myeloma. Cell J (2013) 0.79
Inhibition of BDNF in multiple myeloma blocks osteoclastogenesis via down-regulated stroma-derived RANKL expression both in vitro and in vivo. PLoS One (2012) 0.79
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. J Bone Miner Res (2016) 0.79
Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease. J Clin Invest (2016) 0.78
Design, synthesis, and biological evaluation of bone-targeted proteasome inhibitors for multiple myeloma. Bioorg Med Chem Lett (2013) 0.77
Effect of glycosphingolipids on osteoclastogenesis and osteolytic bone diseases. Front Endocrinol (Lausanne) (2012) 0.76
Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche. Oncotarget (2016) 0.76
Low intensity vibration mitigates tumor progression and protects bone quantity and quality in a murine model of myeloma. Bone (2016) 0.75
Hypercalcaemia and hypocalcaemia: finding the balance. Support Care Cancer (2017) 0.75
Activation status of γδ T cells dictates their effect on osteoclast generation and bone resorption. Bone Rep (2015) 0.75
Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside? Int J Mol Sci (2016) 0.75
Sclerostin expression and functions beyond the osteocyte. Bone (2016) 0.75
Osteocytes and Skeletal Pathophysiology. Curr Mol Biol Rep (2015) 0.75
EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation. Mol Cancer Res (2017) 0.75
Coexistent osteoporosis and multiple myeloma: when to investigate further in osteoporosis. BMJ Case Rep (2015) 0.75